For much of last year, Bausch Health (NYSE:BHC) traded in a range of between $16 - $20. That ended at the start of 2021 when the company pre-announced stronger quarterly results.
After the rally in BHC stock, investors should continue holding it. The company forecast Q4/2020 revenue exceeding $2.2 billion. For FY2020, it will post revenue in the range of $7.8 - $8.0 billion. After COVID-19’s pandemic hurt sales earlier last year, the company is now experiencing a rebound.
CEO Joe Papa said that strong execution across its businesses led to improved results. The cash generation of $1 billion from operations is a key milestone. It already repaid $900 million in debt in 2020. And since it has no debt until 2024, the company may side on investing in the business to accelerate growth.
At the annual healthcare conference, BHC highlighted its latest contact lens technology. The B+L INFUSE, for example, helps patients keep contact lenses from feeling dry. Nearly all patients (97%) said that the lens gave a crisp, clear vision for the day.
BHC continues to reward patient value investors. The B+L unit is delivering on innovation for the daily contact lens market. It is offering a unique proposition: clear lenses that do not dry out. This will lead to market share gains and a BHC higher stock price.
